execut rel investor expect key
stock perform report discuss sub-industri
theme individu stock prospect potenti catalyst
also updat price target roll valuat
organ report five key segment
updat pt roll valuat multipl
theme innov count brand specialti pharma within brand
sub-group horizon bausch
equiti stori highli depend innovation-rel newsflow remain
bullish ow given view teprotumumab rare eye diseas
launch ramp krystexxa sever gout growth momentum exceed
street expect regard bhc ow momentum key franchis new
product launch key stock perform remain sidelin
ew ew regard await updat relat
diversifi xyrem franchis potenti competitor avadel ph
result low sodium xyrem convers prospect regard
view low valuat balanc pipelin uncertainti mid-lat
decad core franchis eros risk innov count brand specialti
pharma detail
theme anim health stock offer durabl growth respit
washington drug price uncertainti think ow ew
well posit durabl growth face broader healthcar
polit uncertainti stock carri rel high valuat
exposur washington human drug price risk current project
revenu compound-annual-growth-rate respect
ep compound-annual-growth-rate benefit bayer ah transact respect
anim health stock offer durabl growth respit washington
drug price uncertainti detail
theme opioid litig gener price-fix investig develop
could caus gener volatil continu believ investor steer
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
clear stock greatest opioid-rel exposur uw
teva uw see risk propos global settlement
final plan separ look forward updat gener price-
fix investig possibl resolut govern inquiri could
percept posit would need assess magnitud potenti
financi penalti risk addit govern oversight busi
practic implic privat sector payer lawsuit opioid
litig gener price-fix develop could caus gener stock
volatil detail
depend upon new product success gener industri like face
on-going secular price headwind remain unclear us industri
perform depend upon time fda approv major new product
exampl share step significantli upon approv gnuvar
dec remain uninspir gener drug stock ew
uw ew teva uw note trade rel
low valuat face less opioid litig exposur set financi
inflect fundament us gener industri
recovery/stabil stori depend upon new product success detail
overweight-r stock offer strong
fundament potenti upsid out-year earn multipl
anticip upward pressur ow consensu project specif
krystexxa teprotumumab sale think transit rare
diseas remain underappreci expect orphan/rheumatolog segment
total compani revenu rise
expect ow share climb wall worri current valuat appear
discount investor concern believ consensu turn focu
bayer transact posit margin expans prospect lt pipelin
potenti next year see potenti share partial
narrow valuat gap ep ep
execut face competit threat bayer uncertainti
theme detail view individu stock prospect
innov count brand specialti pharma
anim health stock offer durabl growth respit washington drug
opioid litig gener price-fix develop could caus gener stock
innov count brand specialti pharma
within brand specialti pharmaceut coverag horizon
bausch equiti stori highli depend upon innovation-rel newsflow
teprotumumab launch ramp krystexxa growth momentum think
con revenue tepro revenu still conserv expect upsid
number pent-up demand moderate-to-sever activ ted patient
support robust launch also upsid scenario tepro approv
earlier pdufa current model tepro sale vs
con separ think krystexxa con sale project also
appear conserv yoy growth believ krystexxa
continu strong growth momentum post one time impact
model sale yoy addit horizon studi
krystexxa use methotrex could boost length treatment drive
increas averag vials/pati come year note horizon exist
peak sale estim assum six vial averag vs full cours
await updat diversifi away xyrem franchis avadel ph
top-line readout updat low sodium xyrem convers prospect
think could potenti execut materi given rapidli
approach gener start separ avadel nightli version
sodium oxyb set deliv ph top-line result consensu
expect low benefit-risk ratio match twice-nightli
xyrem like near-term overhang low sodium
approv look forward management updat convers strategi
pipelin need shot arm view vumer clinic uninspir
limit differenti vs tecfidera management team also convey
strategi switch strategi expand tecfidera surprisingli goe gener
earlier expect could limit uptak vumer payer could
limit access given limit clinic differenti design safer
cancer data date unconvinc given lack monotherapi
respons pr/cr melanoma /renal cell cancer mechan
theoret would efficaci regard low weight gain
zyprexxa current model peak sale lli zyprexxa
today believ payer limit access given gener avail mani gold
standard schizophrenia drug look forward futur newsflow relat
recent acquisit rodin develop first-in-
class oral molecul target specif histon deacetylas hdac complex
intend advanc investig new drug ind -enabl activ rodin
bhc new product growth momentum key believ four bausch signific
seven growth driver strong prospect duobrii lumifi relistor sihi daili
siliq annual run rate vyzulta annual sale run rate disclos
experienc weaker-than-expect uptak lumifi sale annual run
rate relistor franchis annual sale run rate sale breakdown
oral inject disclos exceed expect duobrii/bryhali
launch well long-term potenti depend upon whether payer
support use psoriasi expens biolog ceo papa said
call duobrii payer coverag includ unrestrict prior
author bausch target total access next summer reimburs
improv coupon diminish sale ramp come quarters/year note
bryhali launch nov duobrii launch june sale
disclos product individu sale remain bhc
new product launch note includ
duobrii bryhali launch trend weaken past month
spike recent week latest week data display pullback follow
upward inflect exhibit duobrii launch june bryhali
trulanc trx grow trulanc grew recent week
compar roll absolut weekli continu trend posit
yoy growth seem inflect upward recent week exhibit bhc
complet acquisit certain asset synergi pharma includ trulanc
vyzulta inflect higher recent week vyzulta eutrx inflect upward
recent week exhibit track vyzulta eutrx launch aeri rhopressa
becuas eutrx track actual unit pill vial etc dispens may
better indic volum sinc rhopressa vyzulta script
exhibit duobrii bryhali weekli
duobrii appear iqvia sinc week end june bryhali sinc dec
exhibit trulanc absolut yoy trend encourag
exhibit vyzulta competitor rhopressa extend trx eutrx sinc launch eutrx
track actual unit pill vial etc dispens may better indic volum
sinc rhopressa vyzulta script vari unit
anim health stock offer durabl growth respit
drug price nois appear set persist near term note polit risk
human pharmaceut stock given administr critic drug price
elect year uncertainti longer term expect invest commun continu
debat sustain high us drug price
elect year uncertainti issu human pharmaceut stock
anim health stock base case still divid govern republican
maintain senat democrat control hous elect outcom
imposs predict addit still risk trump administr
advanc intern price index demo medicar part earli
potenti trump administr hh action price demo
democrat presidenti nomin spring
anim health stock offer growth defens characterist think
ow ew well posit durabl growth face
broader healthcar polit uncertainti stock carri rel high valuat
exposur washington human drug price risk share benefit
stellar busi execut management team defens fund flow think
outperform execut core busi bayer
addit defens characterist offer strong durabl
growth prospect current project revenu
compound-annual-growth-rate respect ep compound-annual-growth-rate benefit bayer ah
transact respect stock also continu benefit
favor mega-trend includ rise global demand protein consumpt
increas pet ownership better care companion anim primarili dog
opioid litig gener price-fix develop could
opioid litig remain risk view see three key uncertainti
limit progress universally-accept settlement framework
question whether wide rang state attorney gener local govern
litig agre propos global settlement given state
oklahoma extract judg rule teva settlement
state pend trial may choos join global
await propos global settlement updat wake news end
recal novemb barron articl teva ceo say opioid deal could
done end year state ceo kre schultz said litig compani
face alleg role opioid crisi could resolv end year
think that realist timelin schultz said interview barron recal
propos settlement involv four state feder multidistrict litig mdl
plaintiff attorney part origin releas
mdl negoti class recent consolid vast major local govern
lead counsel cities/counti negoti class file report
decemb state fewer potenti claimant opt
negoti class follow nov opt deadlin impli number
case consolid within mdl increas case
case howev local govern opt includ key opioid
crisi region florida palm beach counti counti west virginia
impli defend could still potenti face import local govern trial
outsid mdl
list plan opioid trial dec plaintiff defend ny
state opioid case provid statu report includ comprehens list
schedul trial date accord statu report opioid-rel
case pend state court includ state attorney gener case counti
municip case least state case brought non-government entiti
major state court case earli stage trial date
schedul follow case discoveri underway see exhibit caveat
trial typic delay settl imposs predict trial
actual occur
plaintiff defend new york state opioid case submit trial date
march may respect plaintiff defend
new york state opioid case submit differ trial pre-trial schedul retail
pharmaci submit separ brief propos trial date oct instead
exhibit list plan opioid trial note vast major state case await updat potenti mdl trial
caveat trial typic delay settl imposs predict trial actual occur
exhibit list plan opioid trial
peopl state california purdu pharma et al orang counti superior court santa ana
state ohio ex rel mike dewin capac attorney gener state ohio mckesson
corpor et al court common plea madison counti ohio
state alabama purdu pharma et al circuit court montgomeri counti alabama
state mississippi purdu pharma et al chanceri court first judici district hind
state louisiana purdu pharma et al judici district court parish east baton
roug state louisiana
state ohio ex rel mike dewin ohio attorney gener purdu pharma et al common plea
court ross counti ohio
state washington mckesson drug corp et al superior court king counti washington
state arkansa et al purdu pharma et al circuit court crittenden counti arkansa second
texa opioid litig district court harri counti texa
state alaska purdu pharma superior court state alaska third judici district
state missouri ex rel eric schmitt offici capac missouri attorney gener purdu
pharma et al circuit court citi st loui state missouri
shelbi counti shelbi counti board commission purdu pharma circuit court
shelbi counti memphi tennesse
state arizona purdu pharma et al superior court pima counti arizona
state arkansa ex rel lesli rutledg attorney gener purdu pharma et al circuit court
state delawar ex rel matthew purdu pharma et al superior court state
state new mexico purdu pharma et al first judici district counti santa fe state new
state georgia teva pharmaceut ltd et al superior court gwinnett counti georgia
crittenden counti et al amerisourcebergen drug corpor et al circuit court crittenden counti
separ look forward updat gener price-fix investig
potenti resolut govern inquiri could percept posit
would need assess magnitud potenti financi penalti risk
addit govern oversight busi practic implic privat
author materi act capac attorney hold
materi intend either legal opinion legal
advic inform provid herein provid possibl outcom
probabl outcom result legal disput controversi depend
varieti factor includ limit parti histor relationship law
pertain case rel litig ip prosecut talent trial proceed
locat juri composit judg examin composit investor contact
legal advisor issu law relat subject matter materi
moder us sale pressur encourag unclear
industri return sustain growth compani gener report better
perform core us busi face annual price volum
pressur franchis commodit necessit new product launch
offset high debt level limit financi flexibl acquir extern growth driver
perform mix septemb teva larg
stabil gener busi gx segment still moder yoy
due lack signific pipelin launch inabl acquir bolt-on deal
sale result came expens margin pressur recal
step sg yoy total compani oper margin declin
rx oper margin also declin
experienc substanti declin due signific
competit top franchis continu price pressur lack pipelin
launch seeexhibit yoy sale growth gener compani
litig overhang high financi leverag constrain gener compani abil
pursu extern transact boost revenu growth given high financi leverag
see exhibit think teva could struggl pursu signific
stock perform depend upon time fda approv major new product
gener product new pipelin launch watch follow
afinitor iqvia brand sale last launch dec
nevakar launch steril inject hospit critic care base
bneulasta expand capac late nov sandoz enter market
bherceptin launch earli dec competitor expect
blantu await regulatori updat vial await litig updat
pen exp resolut patent end
brituxan launch nov brituxan broader label set
launch jan
bherceptin face competit pressur launch juli
exhibit highli lever compani need delev
exhibit debt larg percentag enterpris valu mani spec pharma compani
exhibit teva prgo report sale figur yoy growth
exhibit amneal iqvia gener absolut sale yoy last month
exhibit endo iqvia gener absolut sale yoy last month
exhibit mylan iqvia gener absolut sale yoy last month
exhibit perrigo iqvia gener absolut sale yoy last month
exhibit teva iqvia gener absolut sale yoy last month
im report sale data given month end subsequ month within
quarter monthli sale report week basi im sale data
captur weekli group week month week start januari
week month fall end quarter march june septemb decemb
period extra week ad novemb ensur report month
deviat far calendar month
alkerm under-perform significantli due uninspir busi
perform aristada sale estim vs initi guidanc
pipelin uncertainti vumer trial succeed result
valuat undemand longer term outlook remain cloudi
absolut bear case scenario avert vumer trial succeed
success settl vivitrol patent litig pipelin uncertainti remain overhang
said recent restructur initi bode well improv profit
next year ahead royalti declin mid-decad
market product vivitrol aristada could grow
total revenue howev vivitrol face gener aristada
goe gener earli
high margin manufactur royalti sale grow margin
declin toward
design safer cancer recent data rais
question respons pr/cr monotherapi melanoma /renal
cell cancer mechan theoret would efficaci
today believ payer like limit access given gener
avail mani gold standard schizophrenia drug
vumer immin launch vumer demonstr fewer day key gi symptom
tecfidera clinic uninspir limit differenti note biogen
manag convey strategi switch strategi expand
addit risk earli gener tecfidera entri scenario
gtecfidera come market earlier expect think payer unlik favor
catalyst ahead see catalyst detail
vivitrol aristada sale trend model sale yoy
vs con vivitrol yoy vs con
vumer launch ramp model sale vs con
royalti estimate end market sale
tecfidera patent litig develop note manag team
convey strategi switch strategi expand separ
view even scenario gtecfidera come market
substanti earlier expect switch protect franchis given
limit clinic differenti payer unlik favor vumer
amneal declin significantli due highli disappoint busi
perform two signific guidanc cut due intens competit key franchis
lack signific pipelin launch addit top two execut
replac amneal founder summer
stock re-bas valuat cheap ebitda amneal
certain compel new product opportun lack visibl regard longer-
term revenu earn prospect
outlook pipelin launch management guid complex product pipelin
launch next month expect management
state gcopaxon good likelihood approv launch
like number
margin execut management target gm gx segment last
month gener segment gross margin declin
given competit pressur new management pursu initi improv
chain manag improv gross-to-net sale convers right-siz opex
launch high-valu new product current model gener segment
gross margin expans could
upsid amneal launch high-valu new product
longer term revenu prospect specialti brand depend upon
readout success brand zomig patent protect may
rytari exclus juli come
focu management convey amneal expect ph top line
result end recal previou management convey optim
prospect cite better product vs rytari
line extens dose titrat much simpler
provid better patient experi demonstr signific increas
durat on-tim singl multipl dose studi could
potenti bid dose improv on-tim reduc off-tim
parkinson patient get patient target zone quicker keep
catalyst ahead see catalyst detail
pipelin approv management guid complex product pipelin launch
next month expect
management anticip fda approv gcopaxon await addit
newsflow pipelin approv
ph data readout
bausch stock outperform significantli due solid oper
execut lead financi upsid rel guidanc bhc estim gener
ebitda rel initi guidanc
continu recommend bhc share base upon strengthen growth prospect
mix shift toward new product improv financi leverag believ bhc
remain earli inning turnaround stori valuat also appear
undemand current ebitda especi bhc de-lev
organ revenu growth driven l/int segment xifaxan l/int
total compani revenue like deliv growth due
fx expect continu strong organ yoy growth low-mid singl digit
fade fx headwind help segment acceler report top-line growth
separ model xifaxan grow yoy
growth yoy growth report basi
project total compani sale growth rise compound-annual-growth-rate
new product ramp driver could exceed expect duobrii lumifi
relistor sihi daili
financi leverag expect narr debt manag continu
improv use estim net debt ebitda
yield net leverag continu expect bhc grow ebitda
help reduc net debt/ebitda ebitda caveat bhc like use
cash flow extern busi develop net debt ebitda may
declin much model year
catalyst ahead see catalyst detail
gener sale model trulanc grow
sihi daili launch us launch expect late
potenti bolt-on acquisit expect management remain disciplin
come potenti busi develop activ note management could
potenti issu equiti conjunct bolt-on acquisit could
facilit margin de-lever boost ebitda
elanco stock significantli under-perform vs due concern
core busi perform competit threat investor skeptic
current valuat discount investor concern view believ consensu
turn focu bayer transact posit margin expans prospect lt
pipelin potenti next year current stock valuat undemand
pro forma ep vs ep see potenti share
partial close gap execut face competit threat
bayer uncertainti also expect elanco share outperform healthcar
sector overal due lack exposur potenti washington human drug price
revenu acceler next three year
livestock pressur eas new pipelin product start contribut
bayer transact could help drive doubl ep base upon
pro forma model elanco could achiev signific accret acceler
margin expans stori model oper margin expand
pro forma
catalyst ahead see catalyst detail
requir plan equiti issuanc
bayer ah deal close expect
simparica trio us launch exp earli eu canada
simparica trio label whether trio get puppi claim fda expect
approv trio march
endo stock under-perform larg due opioid litig overhang
face potenti outsiz exposur given histor opioid sale rel
size compani addit management histor provid conserv
guidanc endo deliv result slightli expect management lower
ebitda guidanc midpoint due competit pressur
see risk propos comprehens global opioid settlement final
plan addit bearish cellulit product opportun given
view separ gov price achiev see report endo separ bla
doesnt guarante separ price sep also materi uncertainti
regard durabl key franchis vasostrict adrenalin current
project compound-annual-growth-rate adj ebitda high leverag net debt
ebitda excl potenti opioid liabil potenti strateg constraint
opioid litig could remain overhang believ opioid litig newsflow
set deterior get better comprehens global settlement
still far reach
longer term revenu ebitda growth prospect uncertain addit
uncertainti regard gener industri secular headwind two
profit product adrenalin vasostrict could potenti face competit
come year current model modest gener competit adrenalin start
vasostrict howev time magnitud gener
entri difficult predict
believ endo abl persuad hh price cch
cellulit differ price xiaflex medic indic
endo submit cch cellulit new bla instead supplement bla
xiaflex garner differ brand name separ label cch cellulit
endo state cch cellulit new patient popul
present formul concentr presum endo goal enabl
lower price cch xiaflex howev sinc two product
drug substanc albeit reconstitut differ diluent differ
concentr think hh agre calcul asp xiaflex
independ cch cellulit concern endo commerci
cellulit formul price much lower impli current
xiaflex price would neg implic govern averag
sale price asp calcul xiaflex medic indic reimburs
catalyst ahead see catalyst detail
cch cellulit pdufa date juli
vasostrict total co ebitda growth trend durabl newsflow
notifi board intent retir board seek successor
horizon stock significantli outperform given upsid consensu
project greater appreci teprotumumab sale potenti
compani improv busi mix upsid number larg driven krystexxa
exceed expect track deliv yoy growth vs initi feb
guidanc doubl digit growth
continu expect out-performance see potenti upsid
earn multipl consensu project appear undemand
con krystexxa sale vs teprotumumab sale vs
think compani transit rare diseas remain
underappreci expect orphan/rheum segment total compani
revenu rise
krystexxa growth momentum krystexxa yoy growth subdu due
one-tim impact implement sale impact base
sale project krystexxa track grow yoy excl
hit importantli post impact expect krystexxa continu
strong growth momentum estim sale yoy
view krystexxa con sale project still appear conserv
yoy growth separ management studi krystexxa use
methotrex could facilit broader longer-dur use come
teprotumumab launch ramp price tepro pdufa date slate
price import catalyst stock implic
tepro peak sale potenti base con project think
stock would benefit tepro price refer exist peak
sale project krystexxa assum ave vial impli treatment
cost separ note management manag expect tepro
launch ramp constrain temporari j-code initi tepro could
potenti assign perman j-code juli would go effect
oct model tepro sale vs con note
upsid scenario tepro could approv earlier expect
catalyst ahead see catalyst detail
teprotumumab launch ramp price announc perman j-code
effect date tepro pdufa date perman j-code
could potenti go effect oct
stock perform well given strong xyrem growth
addit bear case scenario stock avert potenti xyrem
competitor wakix pitolis harmoni bioscienc approv narrower-
than-expect indic result wakix unschedul altern
sunosi instead direct competitor xyrem
expect deliv solid growth mid-teen revenu ep yoy growth
led xyrem franchis howev long-term uncertainti linger
equiti prospect still depend compani navig start gener xyrem
competit crucial year avadel nightli
equival xyrem report ph top-line expect low
appear key near term overhang low sodium xyrem altern
approv management like provid updat convers
strategi could potenti occur given need diversifi ahead
xyrem gener even though set earn high royalti gener
note knowledg potenti transact
solid growth outlook project yoy growth revenu
ep revenu ep estim
con respect continu project strong xyrem growth
yoy volum price
await avadel ph data readout low sodium launch
convers strategi expect low avadel view
near-term overhang model impact xyrem franchis
point separ expect redeem prv submit nda jan
approv occur
catalyst ahead see catalyst detail
quarterli result incl growth driver xyrem sunosi vyxeo
potenti diversifi xyrem
avadel nightli equival xyrem ph top-line readout
approv potenti launch ramp includ convers
strategi updat expect redeem prv submit nda jan
significantli under-perform given on-going gener industri
pressur uncertainti financi prospect includ growth trend beyond
continu trade low valuat longer term growth uncertainti
lack visibl long-term revenu ebitda trajectori addit
importantli newco guidanc key equiti stori management convey
newco financi guidanc provid around time close
appear track occur
financi guidanc upjohn expect stand-alon guidanc
earli
financi guidanc newco deal close newco guidanc
key equiti stori management convey
provid around time close
herceptin launch dec competitor expect
fulphila ramp expand capac late nov sandoz
enter space well
avastin opportun
enbrel partner lupin year away
vial pend regulatori front target action date initi aug
receiv form wait hear fda confid
issu resolv
pend litig front expect patent litig resolut end
march expect launch appeal target launch
ex-u rituxan also pipelin
catalyst ahead see catalyst detail
financi guidanc stand-alon upjohn earli
newco guidanc deal close
quarterli result upjohn
phibro stock under-perform due signific pressur china
busi driven reduc demand relat african swine fever
chang regul restrict use certain antibiot
earn reset lower expect busi trend begin stabil sinc
china zero guidanc project phibro earn prospect remain
across variou speci geographi china difficult assess
predict new base project revenu ep compound-annual-growth-rate growth
uncertain core busi prospect magnitud uptak new
product futur invest spend requir
global macro trend continu support phibro anim health busi
grow global popul increas affluenc drive steadi global
demand anim protein consumpt limit natur resourc produc
product pressur continu drive need anim health diseas
quarterli growth trend note limit visibl phibro busi segment
quarterli prospect phibro could exceed miss quarterli project
compani oper nich anim health mineral/chem market
limit industri sourc product trend make difficult forecast
quarterli result addit weather econom volatil impact quarterli
sale individu market
catalyst ahead see catalyst detail
quarterli earn financi result nutrit specialti vaccin
speci market trend cattl especi
 activ busi develop
stock outperform due three factor view
valuat recoveri dec investor overreact potenti tax liabil
disclosur percept safe lack opioid liabil risk within
specialti pharmaceut sub-sector enthusiasm new management team
could near term upsid number driven organ growth benefit
easier yoy comp specif infant nutrit csca singl
largest headwind sub-seg expect return growth start
howev potenti tax liabil key overhang remain cap
upsid potenti addit lack visibl organ consum growth
consum segment support yoy growth head
expect consum busi benefit full year ranir inclus
partial off-set pet health sale organ consum growth easier yoy
comp project revenu grow consum rx
ep grow yoy con revenue ep
margin expans outlook management execut well expand margin
oper margin csca csci
respect expect management continu drive om expans driven
part management cost save program project momentum current
model om csca csci respect
potenti guidanc chang chang way compani provid
guidanc expect fewer segment target detail go forward look
forward manag new guidanc framework februari
tax liabil uncertainti latest disclosur potenti ir tax liabil add tax
overhang three major tax disput total claim regard irish tax
liabil high court schedul hear judici review proceed
april decis expect
catalyst ahead see catalyst detail
consum quarterli result vs expect consum segment key driver
potenti gener rx exit action crystal valuat gener busi
potenti fda approv launch gproair
teva stock significantli under-perform mainli due exposur
on-going opioid litig addit ajovi launch ramp rel
disappoint teva receiv fda approv three key gener
launch restasi nuvar forteo
expect on-going opioid litig overhang persist continu believ
signific uncertainti regard whether wide rang state local
govern litig agre propos global settlement addit teva
face us price fix litig govern expand inquiri includ much
larger number product spring privat insur file lawsuit recoup
money spent fall addit uncertainti regard
recovery/stabil gener industri north america gener total co
revenue ajovi ramp/uptak cgrp competit intensifi
copaxon eros high leverag combin litig uncertainti also may
limit compani acquir materi bolt-on growth driver
solid busi execut plu cost cut ahead fundament posit
manag execut well cost cut stabil us gener grow
austedo address financi leverag issu think teva could
announc anoth round cost cut conjunct result februari
opioid litig overhang like persist view propos
comprehens global settlement may final plan recent
report list plan opioid trial dec
pipelin note truxima brituxan launch nov bherceptin
expect launch late restasi nuvar event
forteo expect launch teva brituxan narrow
label biosimilar rituxan set launch januari
teva bherceptin face competit pressur launch juli
biocon/mylan launch feb launch nuvar
opportun could somewhat competit market amneal dr
reddi forteo signific opportun teva need secur fda
approv look forward addit pipelin disclosur februari
includ biosimilar candid
ajovi sale prospect launch underwhelm date note
cgrp competit could intensifi
copaxon futur rate declin estim current us copaxon
oper margin expect pressur acceler if/when anoth
gener copaxon approv note amneal cite gcopaxon potenti
catalyst ahead see catalyst detail
gener stabil austedo cgrp growth
potenti addit cost save initi
opioid gener price fix litig newsflow
potenti gforteo launch
zoeti stock significantli outperform driven except busi
execut -- zoeti beaten con ep nine consecut quarter defens
fund flow given washington human drug price risk posit pipelin
newsflow management expect fda approv simparica trio puppi claim march
fundament remain strong livestock present easi yoy comp head
defens posit also continu support premium valuat
elect year said market highli focus simparica trio potenti
success zoeti introduc above-expect sale project trio
order meet investor expect trio need approv march
puppi label claim
strong revenu growth support companion anim new product easi
yoy comp livestock project revenue ep growth
companion anim livestock respect
continu model strong growth companion anim led apoquel
yoy cytopoint simparica incl trio livestock expect
segment return growth follow declin
driven asf pressur
simparica trio puppi label launch time key stock driver await
potenti fda approv simparica trio come month clariti
whether trio label includ use puppi manag expect simparica
one activ ingredi sarolan trio three activ ingredi
sarolan moxidectin pyrantel embon given simparica secur
puppi label ad addit activ theoret would make
sarolan compon safer use earlier remain seen trio succeed
get puppi label note management state surpris
simparica obtain puppi claim design trio trial base upon
catalyst ahead see catalyst detail
quarterli earn apoquel simparica cytopoint sale trend
simparica trio us launch expect earli eu canada
simparica trio label whether trio get puppi claim fda expect complet
review end zoeti plan launch april
quarterli sale result monthli rx trend
northern district west virginia vs judg could rule
district delawar vs gx compani judg could
rule implic vumer competit landscap
expect approv launch submit nda
newsflow updat data artistri ph artistri
expect approv launch
pipelin newsflow exp complex product launch next
month updat relat competit top franchis
expect approv launch
uptak launch ramp lumifi duobrii bryhali sihi daili relistor
vyzulta siliq trulanc
quarterli updat cash flow oper de-lever progress
loe updat apriso date certain
us launch expect late
updat relat potenti gxifaxan threat bhc file lawsuit vs
sandoz alleg patent infring xifaxan
overgrowth sibo post-operative crohn diseas ohe expect
complet interim analysi
potenti equiti issuanc conjunct bolt-on acquisit could
facilit margin de-lever boost ebitda
potenti resolut investig litig matter
bayer ah full-year result
depend anti-trust discuss
trifexi credelio interceptor simparica trio us launch exp earli eu canada
trifexi credelio interceptor simparica trio label whether trio get puppi claim fda expect
complet review end launch expect shortli
newsflow relat rumensin competit landscap impact due
huvepharma grumensin potenti risk addit gx
updat cost optim initi margin expans progress
speci market trend cattl especi
updat norway regulatori approv prospect potenti approv
nevakar launch steril inject hospit critic care base
quarterli updat cash flow oper de-lever progress
newsflow relat durabl gener threat
pdufa date perman j-code could assign juli effect
oct
potenti competitor krystexxa ph data readout
interim data top-lin statist superior data
quarterli result incl growth driver xyrem sunosi vyxeo
ex-u launch anticip eu approv earli
ph pvod studi interim analysi first patient
ph top-line readout nightli equival xyrem
approv launch ramp includ convers strategi updat
expect redeem prv submit nda jan
ph data readout idiopath hypersomnia estimate primari
expect initi ph studi treatment patient essenti tremor
acquir cavion
ph data readout treatment all/lbl estimate primari
potenti updat erwinaz renew pbl current licens
porton biopharma limit sell product
quarterli result upjohn stand-alone
newco financi guidanc deal close
fda warn letter morgantown facil updat
northern district west virginia vs judg could rule mid-
ms est district delawar vs gx compani judg could
rule ms est
requir notifi revanc later day
date revanc provid certain deliver
launch uptak add competitor approv amneal expect gcopaxon
launch
launch uptak add competitor approv expand capac late
sandoz enter market well
launch uptak add competitor approv launch earli dec
await regulatori updat vial await litig updat pen
exp resolut patent end
us gener price trend sale
quarterli earn financi result nutrit specialti vaccin
speci market trend cattl especi
 activ busi develop
quarterli result vs expect consum segment key driver
rx exit action crystal valuat gener busi
potenti fda approv launch
tax liabil updat high court hear judici review proceed
apr irish tax liabil
 activ busi develop
us gener price trend sale
gener stabil austedo cgrp growth
quarterli updat free cash flow de-lever progress
potenti fda action gcopaxon applic amneal synthon biocon
dr reddi
launch uptak launch nov brituxan broader label
set launch jan
launch uptak add competitor approv set launch late
face competit pressur launch juli biocon/mylan
potenti approv launch gx filer includ amneal dr reddi
potenti approv launch
quarterli earn apoquel simparica cytopoint sale trend
simparica trio us launch exp earli eu canada
simparica trio label whether trio get puppi claim fda expect
complet review end launch expect shortli
updat relat mab pipelin launch expect cat dog
speci market trend cattl especi
updat pt roll valuat multipl
pt
valuat methodolog risk associ recommend rate price target referenc report pleas contact client support follow us/canada hong kong
latin america london singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
us specialti brand gener
price
price
spec brand gx mean
spec brand gx median
valuat methodolog risk associ recommend rate price target referenc report pleas contact client support follow us/canada hong kong
latin america london singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
pt repres revenu lower spec pharma
median see warrant given pipelin uncertainti
long-term pressur royalti revenu
pipelin surpris upsid earn expect extern
strateg action boost share cancer data encourag
revenu higher base case due key product perform
manag drive better earn cash flow execut
pipelin uncertainti persist market product perform line
expect demonstr strong initi result vumer
uptak modest market product vivitrol aristada line
market product fall short data disappoint delay
launch vumer beyond vivitrol aristada growth slower
anticip drive total revenue base case disappoint
clinic trial partner biogen delay launch vumer
rate equal-weight rel
prospect balanc low stock
low expect pipelin
schizophrenia vumer
valuat appear low share
trade revenu
may posit pipelin cost
vivitrol aristada
financi result rel expect
launch trend vumer
pipelin newsflow particular
risk achiev price
result pipelin surpris
beyond cash flow pressur
wide risk reward cone reflect volatil natur stock
wide risk reward cone reflect volatil natur stock
pt base ebitda slight premium
current gener peer mean reflect less brand opioid
litig risk slightli stronger ebitda compound-annual-growth-rate
vs gener peer teva mean low-singl digit
ebitda
ebitda
result forecast fda approv major new gener candid
yield upsid amneal beat expect new product margin
ebitda project futur accret
ebitda
ebitda
project high singl digit ebitda growth driven new launch
note uncertainti project compound-annual-growth-rate revenue
ebitda driven pipelin contribut cost constraint time
new product launch imposs predict forecast subject
ev/ebitda
ev/ebitda
busi deterior new launch delay amneal
face litig problem buy group competit pressur worsen
drive gener busi downsid pipelin opportun delay ebitda
project neg litig newsflow hurt stock
share trade low price-to-earnings earn
growth prospect unclear
driven pipelin contribut
high leverag year-end net
debt divid adj ebitda
financi strateg constraint
litig continu overhang
amneal brand opioid
exposur like peer
financi result rel expect
updat gener price fix opioid
extern busi develop
risk achiev price
upsid risk improv gener price
environ result expect
beat favor resolut price fix
opioid litig value-enhanc
downsid risk result
neg develop gener price
environ cost synergi miss
price-fix alleg opioid litig
legal challeng
pt base ev/ ebitda discount
specialti pharma peer
bull case ebitda
bull case ebitda
result surpris upsid manag turn busi around sale
expect driven new product launch lead ebitda
upsid investor enthusiasm acceler growth prospect
improv leverag profil grow boost multipl
base case ebitda
base case ebitda
new product launch fade loe impact help bhc drive durabl revenu
growth see clear sign improv encourag new
pipelin opportun expect loss exclus impact dissip
time new product launch contribut growth
bear case ebitda
bear case ebitda
manag struggl execut pipelin product disappoint
downsid new product launch ramp mediocr product xifaxan face
new gener challeng us rx drug price come pressur litig
newsflow concern
revenu ebitda return
growth drive stock multipl
expect new product ramp
acceler neg impact loss
exclus fade caus posit
inflect revenu growth
gradual debt paydown improv
debt/ebitda metric come year
bhc wide bull-to-bear skew given
high leverag small chang ev enterpris
valu drive larg chang equiti valu
product xifaxan growth newsflow
 ultra contact len franchis vyzulta
debt paydown refinanc
quarterli financi result guidanc
de-lever progress balanc sheet
risk achiev price
busi execut disappoint bausch
guid consensu
neg litig develop
bausch may invest
intern support long-term growth
us drug price could pressur
fda could delay approv new product
pressur gener
ex-u busi could miss due fx and/or
bausch high beta stock could
under-perform market downturn
overweight see strong
ep plu attract stock valuat
pt base pro forma ep discount
ep project pro forma ep compound-annual-growth-rate
pro forma bull case ep
bull case ep
result forecast due new product strength delay competit
entrant faster margin expans revenu upsid driven key
franchis strength new pipelin contribut competit entrant
simparica trio delay bayer transact synergi realiz faster
expect ep project
pro forma base case ep
pro forma base case ep
revenu growth significantli improv margin drive mid-teen ep
growth project pro-forma revenu growth
oper margin expand stand-alone pro
forma believ management deliv margin expans target
driven improv cost save initi improv busi mix
expect pipelin bear fruit medium-long term
pro forma bear case ep
pro forma bear case ep
competit pressur asf caus revenu shortfal bayer deal
disappoint global economi weaken multipl competit entrant enter
broad-spectrum endectocid market beyond simparica trio
companion anim second gener rumensin launch african swine fever
divestitur requir deal less accret expect global econom
weak drive demand downsid ep project
expans ebitda
expans
see potenti margin upsid
cost save earlier/larg project
pipelin progress drive
greater investor enthusiasm medium-
financi result rel expect
product introduct compet
extern busi develop
risk achiev price
trio approv fda ahead spring
perform surprisingli well face new
imvixa sea lice food anim sale rebound
follow asf pressur save
expect compel new pipelin
product disclos anti-trust author
bayer transact accret bigger/soon
expect elanco de-lev balanc
sheet faster expect
competit entrant enter broad-
swine fever spread caus
antibiot busi face pressur
anticip management fail deliv substanti
execut erp system implement
goe awri weather problem anim
bayer share pro
forma share potenti futur stock sale
wide risk reward cone reflect volatil natur stock see higher
reflect volatil natur stock see higher
probabl downsid
probabl downsid
pt base ebitda target multipl
gener peer averag given project long-term ebitda
declin high leverag litig risk
bull case ebitda
bull case ebitda
gener brand exceed expect cellulit product
success anticip opioid litig newsflow surprisingli
encourag gener xiaflex brand sale expect
drive ebitda expect cch cellulit success
differenti price vs medic indic opioid litig newsflow
encourag small expans ev drive larg equiti upsid given
base case ebitda
base case ebitda
valuat appear low project long-term result consensu
concern litig risk assum cellulit disappoint opioid
litig gener price fix alleg uncertainti persist endo brand
opioid litig exposur yield greater litig risk gener pure-play
cch cellulit unabl differenti price vs medic indic
bear case ebitda
bear case ebitda
financi result forecast endo abandon xialfex cellulit
opioid gener price fix litig concern grow gener sale
squeez competit pressur deterior price
environ brand xiaflex disappoint ebitda expect
multipl contract neg opioid litig newsflow
valuat appear low project long-
term result consensu see
litig risk addit
signific uncertainti regard
durabl key franchis adrenalin
vasostrict
high leverag year-end net
debt divid adj ebitda
financi strateg constraint
yield greater litig risk gener pure-
gener price trend new launch
quarterli sale momentum brand
fda action cch cellulit
risk achiev price
upsid risk base gx busi prove
resili expect gener restructur
lead profit busi
expect brand surpris upsid cch
cellulit newsflow better expect
lower debt boost price-to-earnings
sever declin project key
expect endo abandon cch
gener price-fix alleg opioid
ebitda appli multipl premium
mean higher valu rheumatology/orphan drug franchis
grown repres profit key driver krystexxa grow
strongli expect solid teprotumumab launch rise
bull case ebitda
bull case ebitda
krystexxa tepro sale higher expect enhanc prospect
initi sale uptak stronger anticip revenue forecast
ebitda drive multipl expans boost prospect
base case ebitda
base case ebitda
upward pressur long-term sale prospect mix shift toward
orphan/rheum drive valuat higher posit orphan/rheum growth
offset primari declin krystexxa continu grow strongli
teprotumumab approv via prioriti review boost prospect
manag could pursu addit transact enhanc compani
bear case ebitda
bear case ebitda
launch surprisingli delay krystexxa sale disappoint primari
disappoint due polit price scrutini commerci pbm pressur
revenue forecast ebitda teprotumumab launch
delay unpredict reason multipl contract
overweight share base
upon compani transit
orphan/rheum expect
compani valuat expand
segment earn rise
estim
teprotumumab compel pipelin
asset could launch earli
project us sale
primari uncertainti includ risk
polit scrutini futur pbm pressur
remain overhang alreadi model
franchis step significantli
next five year
rheumatology/orphan
profit momentum product krystexxa
actimmun ravicti buphenyl procysbi
primari care/specialti
profit momentum product vimovo
duexi pennsaid rayo migergot
action sale uptak
quarterli result financi guidanc
krystexxa sale ramp futur studi
teprotumumab approv launch
risk achiev price
upsid risk financi result
orphan segment grow faster
anticip teprotumumab sale uptak
bigger/fast expect horizon
downsid risk kryxtexxa sale lower
expect payer access/pr pressur
face scrutini high price teprotumumab
approval/launch surprisingli delay
horizon could overpay potenti
and/or take much debt key drug
pt base base case ep
earn highli concentr singl franchis xyrem
total compani sale face patent cliff
bull case ep
bull case ep
sales/ep forecast plu creat signific valu xyrem
vyxeo sale exceed estim drive ep project investor
respond posit ph efficacy/safeti result materi
base case ep
base case ep
anticip strong earn growth near-term see price-to-earnings multipl
constrain due xyrem-rel uncertainti project ep compound-annual-growth-rate
high singl digit gener threat xyrem repres
nightli candid match xyrem benefit-risk profil
bear case ep
bear case ep
in-lin product sale forecast avadel competit threat hurt multipl
stock react neg xyrem vyxeo sale forecast
yield ep project avadel once-nightli surprisingli
deliv equival benefit-risk ratio twice-nightli xyrem investor react
neg multipl trade low seen select large-cap biotech
equal-weight strong near-
medium term growth prospect balanc
longer term uncertainti
revenu ebitda ep
 could enhanc prospect
diversifi away xyrem franchis
short-term impact share difficult
predict sinc expect risen
signific relianc xyrem franchis
total compani sale
expect next-gen fail retain
major xyrem sale gener enter
market even success
convert xyrem patient prior
believ payer unlik pay
patient
xyrem gener avail
financi result rel expect
vyxeo sale outlook label expans
extern busi develop
risk achiev price
upsid risk result expect
prospect xyrem transit strategi
low sodium value-enhanc
downsid risk result
threat rise scrutini drug price product
lawsuit problemat legal
pt base upon stand-alon ebitda
estim ev stand-alon ebitda
net debt yield equiti valu share price
base share valuat low end
new product launch moder price pressur cost effici drive
ebitda expect price fix issu resolv minim penalti
new product launch improv price trend drive revenu upsid
effici add ebitda drive ebitda project ev/ebitda
expand improv result plu us price fix litig resolut
ev/bas case ebitda
ev/bas case ebitda
out-year earn consensu low valuat
counterbal rel consensu project lower gross margin due
competit issu higher spend given reinvest requir
project stand-alon ebitda growth ep growth
ev/bear case ev/ebitda
ev/bear case ev/ebitda
financi wors expect due competit pressur new
share price pressur worsen new product launch fall short
expect yield ebitda forecast us price fix litig
fear rise despit lack exposur brand opioid promot
financi outlook uncertainti balanc low
revenue ep extern
forecast continu lower
financi leverag rule
risk signific litigation-rel cash
predict outcom
govern privat lawsuit relat
view opioid litig minor
risk brand
price trend competit landscap
quarterli sale margin profit cash
flow rel expect
financi result guidanc updat
success new product launch
resolut gener industri price fix
risk achiev price
result could fall short expect
due competit pressur new product
reinvest aggress
intern extern busi
develop boost growth caus
involv may result fine claim
execut wrongdo
opioid litig could troubl
expect even though role
limit minor gener manufactur
pt base calendar year ep
target price-to-earnings toward middl phibro long term one
standard deviat price-to-earnings rang
ep
ep
growth higher expect phibro particip industri
consolid sale upsid nutritionals/vaccin emerg market
drive ep forecast phibro particip industri consolid
ep
ep
phibro deliv in-lin anim health result growth led nutrit
vaccin estim anim health segment grow includ
increas nutrit specialti increas vaccin off-set
declin mfa project mid high singl digit ep growth next
two year compound-annual-growth-rate
ep
ep
sale shortfal caus downsid financi outlook stock multipl
competit pressur econom disrupt caus busi shortfal
nutrit specialti vaccin growth disappoint franchis
outsid china declin ep project price-to-earnings multipl contract
weaker result
slightli posit risk-reward skew
current level earn
expect appear re-set
achiev level out-year earn
growth prospect cloudi
global macro trend continu support
global popul increas affluenc
drive steadi global demand anim
resourc produc product pressur
continu drive need anim
note limit visibl phibro
busi segment quarterli prospect
phibro could exceed miss quarterli
project compani oper nich
anim health mineral/chem market
limit industri sourc product
trend make difficult forecast
weather econom volatil drive
could drive stock out-performance
macro trend drive global demand
quarterli financi result rel
product launch penetr
risk achiev price
upsid risk price target includ
faster uptak new product return
growth greater-than-
engag extern strateg action
particip industri consolid drive
greater stock appreci anticip
downsid risk price target includ
neg regulatori action key
withdraw mecadox diseas weather
disrupt certain anim speci demand
pt base ep target price-to-earnings discount
mean lower end standard
deviat rang con ntm ep reflect potenti
tax liabil model
consum segment perform better expect margin profil improv
plu launch gener proair drive ep expect tuck-in
favor outcom irish tax disput stock re-rat higher
deliv result line expect financi uncertainti
persist grow revenu low singl digit ep mid-singl
digit manag execut well improv consum busi execut
rx busi tax disput uncertainti persist
busi pressur worsen rx exit value-destruct tax disput
newsflow concern consum busi growth disappoint due
competit pressur rx struggl due price pressur lack new
launch deterior margin profil drive ep downsid rx exit hurt
sharehold valuat due dis-synergi low valuat face
manag drive consum busi
improv balanc rx
busi tax disput uncertainti
project modest revenu
earn growth come year
organ compound-annual-growth-rate revenu
await clariti rx busi prospect
exit plan
assum tax litig take year
north american store-brand
counter medicin adj op incom
intern consum over-the-counter adj
op incom franchis omega
manag work turn around
prescript rx gener adj op
incom leader gener topic limit
competit gener nich high
corpor overhead adj op
quarterli result guidanc updat
feb
gproair fda approv launch
risk achiev price
new product launch delay
invest spend enhanc prospect
higher anticip
dilut associ rx exit wors
expect
problemat newsflow rx price-fix
investig recal offic
examin fbi year ago part
investig
pt base ev/ebitda discount
gener peer averag project ebitda compound-annual-growth-rate
bull case ebitda
bull case ebitda
us gener trend inflect posit ajovi revenu cost cut exceed
expect opioid litig newsflow encourag ebitda higher
base case due improv us gener trend ajovi sale upsid
higher margin manag deliv cost save forecast favor
resolut gener price fix alleg opioid litig multipl
base ebitda
base ebitda
project long-term result consensu see litig risk high
leverag drive stock downsid limit visibl longer term
revenu growth prospect concern litig uncertainti
gener price price opioid continu constrain teva stock multipl
teva brand opioid litig exposur yield greater litig risk
bear ebitda
bear ebitda
earn disappoint due competit pressur execut challeng
new product launch delay unfavor resolut on-going litig
ebitda lower base case due gener shortfal ajovi key new
brand product sale ramp disappoint propos global opioid settlement
final litig risk mount
valuat appear low project long-
term result consensu
concern litig risk
high leverag year-end net
debt divid adj ebitda
financi strateg constraint
yield greater litig risk gener
opioid litig us price fix
new product austedo ajovi sale
flow trend de-lever
opioid litig us gener price fix
risk achiev price
opioid litig newsflow
copaxon sale higher/low
 receiv positively/neg
base case ep target multipl high
end histor rang given strong pipelin prospect project
bull case ep
bull case ep
new product upsid drive faster revenu growth project zoeti
pursu value-enhanc organ ep upsid plu upsid
yield ep forecast tuck-in could enhanc
base case ep
base case ep
project low double-digit ep growth driven growth key companion
anim product project compound-annual-growth-rate revenu growth ep compound-annual-growth-rate
macro trend posit price annual global
roll-out new product give us confid project
bear case ep
bear case ep
fda delay approv simparica trio face lower end-market growth
approv simparica trio march approv without
puppi claim zoeti face new competitor key companion anim franchis
compani miss ep estimate price-to-earnings multipl contract
zoeti combin compel
ep growth
posit new product develop
revenu perform margin
livestock rev demand
meat milk project least doubl
next year due larg part
popul growth increas
affluenc emerg market
companion anim rev
global spend pet grow
fda action simparica trio approv
expect march
quarterli result guidanc updat
new product ramp rel
zoeti becom activ deploy
capit acquir products/compani
competitor perform better/wors
competitor could launch product
compet directli key zoeti growth
risk achiev price
new product approv delay
margin expans fail materi
new govern regul legisl
impact growth
shortfal certain market
dollar strength rel foreign
valuat methodolog risk
valuat methodolog risk associ price target referenc
research report pleas contact client support follow us/canada
altern may contact invest repres morgan
stanley research broadway attent research manag new york ny
